QVAR® Gets More Medicine Where It Needs to Go3
- Most ICSs aren’t formulated to reach inflammation in the small airways — only QVAR can reach the entire lung3
- QVAR outdistances fluticasone in improving lung function4
- QVAR delivers up to 58% lung deposition compared with 12-13% for fluticasone CFC1,3,5
- QVAR is the first and only small particle ICS indicated for patients as young as 5 years of age6
QVAR: a small-particle ICS, designed to reach inflammation in even the smallest airways3
Your Asthma Patients Can Start on Q and Stay on Q ―
Because QVAR Goes the Distance.
References:
- Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol. 2002;109(2):S447-S460.
- Yanai M, Sekizawa K, Ohrui T, et al. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol. 1992;72:1016-1023.
- Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone*: a cross-over study in healthy volunteers. Chest. 2002;122:510-516.
- Thongngarm T, Silkoff PE, Kossack WS, Nelson HS. Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma. J Asthma. 2005;42:257-263.
- Leach C. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol. 1999;104:S250–S252.
- QVAR Prescribing Information, IVAX Laboratories Inc., 2006.
080712